Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...
The in vivo gene editing pipeline is also advancing ... in their research and potential market impact. Additionally, Crispr Therapeutics AG plans to engage with regulators regarding B-cell ...
including notable advancements in Crispr Therapeutics AG’s pipeline and strategic partnerships. The company has shown promising progress with the Casgevy launch, evidenced by an increase in ...
The Motley Fool on MSN16d
2 Magnificent Stocks to Buy That Are Near Their 52-Week LowsThe biotech has several other exciting candidates beyond CX112. There are some risks associated with CRISPR Therapeutics. Its pipeline programs, even CX112, could flop, for instance, a typical issue ...
CRSP Boasts Encouraging CRISPR-Based Pipeline Programs CRISPR Therapeutics is pursuing the development of CRISPR candidates to create novel CAR-T cell therapies. Management is developing two next ...
A look at Intellia Therapeutics, Inc. and Editas Medicine, Inc., including their restructuring and pipeline prioritization. Read more about EDIT and NTLA stocks here.
CRISPR Therapeutics' stock decline is likely influenced ... CRISPR has enough in its own pipeline to worry about and fund. I just don’t see it. There’s also been some recent speculation ...
In the closing of the recent trading day, CRISPR Therapeutics AG (CRSP ... The fall in CRSP stock can be attributed to a lack of pipeline updates. Despite securing approval for its first marketed ...
Beyond Casgevy, CRISPR Therapeutics continues to advance its pipeline across multiple therapeutic areas. The company's allogeneic CAR-T cell therapy programs, particularly CTX112 for B-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback